Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
August 07, 2023 07:00 ET
|
Praxis Precision Medicines, Inc.
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in the composite qEEG measured through 10-day treatment period Ongoing PRAX-628 Phase 2 Photo-Paroxysmal...
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
August 01, 2023 08:30 ET
|
Avenue Therapeutics
MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Nexstim Receives Order for NBS System 5 from Boston VA Hospital
July 31, 2023 06:00 ET
|
Nexstim Oyj
Press release, Helsinki, 31 July 2023 at 1 PM (EEST) Nexstim Receives Order for NBS System 5 from Boston VA Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new...
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
July 24, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande
July 20, 2023 10:55 ET
|
CROSSJECT
Communiqué de presse Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande ...
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
July 20, 2023 10:55 ET
|
CROSSJECT
Press Release Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand Exclusive licensing, distribution and...
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
July 20, 2023 01:30 ET
|
CROSSJECT
Press Release Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand Exclusive licensing, distribution and...
Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande
July 20, 2023 01:30 ET
|
CROSSJECT
Communiqué de presse Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande ...
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
July 19, 2023 06:00 ET
|
Catalyst Pharmaceuticals, Inc.
Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters...
NeuroSigma Establishes Singapore Subsidiary
July 12, 2023 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”) today announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation (“NeuroSigma Singapore”), representing...